NEW YORK and SAN DIEGO, Sept. 7, 2016 /PRNewswire/ -- Promosome LLC ("Promosome"), a privately-held synthetic biology and biopharmaceutical company, announced today that is has initiated its fourth exploratory collaboration to evaluate its proprietary suite of mRNA-based reengineering tools for use in the emerging field of nucleic acid therapeutics.
Promosome's unique mRNA reengineering technology is derived from the groundbreaking discoveries of the late Nobel laureate Dr. Gerald Edelman and his colleague, Dr. Vincent Mauro, who serves as Promosome's chief scientific officer. Their new model for protein translation led to the development of a suite of proprietary mRNA reengineering tools that optimize ribosome recruitment, eliminate false starts in translation initiation, and ensure message stability while promoting the health of the cells tasked with this production. Promosome's modifications to non-protein coding regions of mRNA enhance translation efficiency without introducing the risk of synonymous mutations, which may be particularly complicating for the safe delivery of nucleic acid therapeutics.
"We are encouraged by the reception of Promosome's mRNA technology platform in the field of nucleic acid therapeutics," said Chris LeMasters, chief executive officer of Promosome. "In this space, there is a need to ensure that the delivered mRNA sequence is translationally efficient, leading to high levels of expression, while avoiding modifications that might impact drug safety. Our ultimate goal is to partner with the leaders in nucleic acid therapeutics so that the benefits of our technology will support the successful advancement of these promising new drug modalities."
Promosome's exploratory nucleic acid therapeutic collaborations this year include evaluations of the Company's technology in mRNA therapeutics, gene therapy products, and DNA/RNA vaccines. Promosome also has a strategic partnership with GE Healthcare Life Sciences in the biotherapeutics manufacturing space, where its technology is being used to develop a mammalian cell line generation service focused on delivering increased expression levels for hard-to-manufacture biotherapeutics.
About Promosome LLC
Promosome is a synthetic biology and biotherapeutics company located in San Diego. Promosome's proprietary translation technologies produce meaningful improvements in the expression and secretion characteristics of mRNA. Importantly, these improvements are gained through alterations to non-protein coding regions of mRNA: powering translational efficiency without introducing the risk of synonymous mutations associated with traditional codon optimization. Synonymous mutations can lead to immunogenicity in engineered protein drugs and may be particularly complicating in the safe delivery of mRNA-based therapeutics.
Promosome is using its technology platform to make important medicines more readily accessible to patients worldwide. The company's internal drug development pipeline includes promising hard-to-express protein therapeutics that would not be practical for development without the mRNA translation improvements produced by Promosome's proprietary technology. Promosome's first internal biotherapeutic program is a recombinant human protein addressing alpha-1 antitrypsin deficiency. Promosome is also applying its technology in the development of gene therapies, mRNA therapeutics, and DNA/RNA vaccines through partnerships with leading developers of nucleic acid therapeutics.
For more information on Promosome, please visit our website at www.promosome.com.
10865 Road to the Cure, Suite 168
San Diego, CA 92121
+1-858-622-1026, ext. 1004
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/promosome-announces-exploratory-collaborations-in-nucleic-acid-therapeutics-300323115.html
SOURCE Promosome LLC